ondansetron has been researched along with Brain Neoplasms in 10 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists." | 9.34 | Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. ( Affronti, ML; Desjardins, A; Friedman, HS; Healy, P; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Patel, MP; Peters, KB; Randazzo, DM; Woodring, S, 2020) |
| "This prospective, randomized, placebo-controlled, double-blind study was designed to evaluate the efficacy of ondansetron, a 5-HT3 antagonist, in preventing postoperative nausea and vomiting (PONV) after elective craniotomy in adult patients." | 9.09 | Effect of prophylactic ondansetron on postoperative nausea and vomiting after elective craniotomy. ( Bhatia, A; Dash, HH; Kathirvel, S; Prakash, A; Shenoy, S; Subramaniam, B, 2001) |
| "To justify the use of ondansetron as a preventive treatment for postoperative nausea and vomiting (PONV) of adults and children in neurosurgery." | 8.86 | [Ondansetron: a meta-analysis on its efficacy to prevent postoperative nausea and vomiting after craniotomy in adults and children]. ( Dailler, F; Duflo, F; Frost, F, 2010) |
| "A 1-year-old girl with stage-IV neuroblastoma developed ondansetron hydrochloride anaphylaxis." | 7.76 | Anaphylactic reaction owing to ondansetron administration in a child with neuroblastoma and safe use of granisetron: a case report. ( Batu, ED; Büyükpamukçu, M; Civelek, E; Demir, HA; Saçkesen, C; Yalçın, B, 2010) |
| " K(+)-flux response mechanisms to the antiemetics ondansetron and granisetron were therefore correlated to malignant glioma cell (Mg251) volume response to estramustine phosphate (EMP) in vitro." | 7.71 | Ondansetron but not granisetron affect cell volume regulation and potassium ion transport of glioma cells treated with estramustine phosphate. ( Behnam-Motlagh, P; Grankvist, K; Henriksson, R; Sandström, PE, 2002) |
| "CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists." | 5.34 | Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. ( Affronti, ML; Desjardins, A; Friedman, HS; Healy, P; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Patel, MP; Peters, KB; Randazzo, DM; Woodring, S, 2020) |
| "This prospective, randomized, placebo-controlled, double-blind study was designed to evaluate the efficacy of ondansetron, a 5-HT3 antagonist, in preventing postoperative nausea and vomiting (PONV) after elective craniotomy in adult patients." | 5.09 | Effect of prophylactic ondansetron on postoperative nausea and vomiting after elective craniotomy. ( Bhatia, A; Dash, HH; Kathirvel, S; Prakash, A; Shenoy, S; Subramaniam, B, 2001) |
| "To justify the use of ondansetron as a preventive treatment for postoperative nausea and vomiting (PONV) of adults and children in neurosurgery." | 4.86 | [Ondansetron: a meta-analysis on its efficacy to prevent postoperative nausea and vomiting after craniotomy in adults and children]. ( Dailler, F; Duflo, F; Frost, F, 2010) |
| "A 1-year-old girl with stage-IV neuroblastoma developed ondansetron hydrochloride anaphylaxis." | 3.76 | Anaphylactic reaction owing to ondansetron administration in a child with neuroblastoma and safe use of granisetron: a case report. ( Batu, ED; Büyükpamukçu, M; Civelek, E; Demir, HA; Saçkesen, C; Yalçın, B, 2010) |
| " K(+)-flux response mechanisms to the antiemetics ondansetron and granisetron were therefore correlated to malignant glioma cell (Mg251) volume response to estramustine phosphate (EMP) in vitro." | 3.71 | Ondansetron but not granisetron affect cell volume regulation and potassium ion transport of glioma cells treated with estramustine phosphate. ( Behnam-Motlagh, P; Grankvist, K; Henriksson, R; Sandström, PE, 2002) |
| "No difference in rescue antiemetic treatment or postoperative nausea and vomiting at specific time intervals (0-6 and 6-24 h postoperative period) was seen among the three groups." | 2.73 | Scheduled prophylactic ondansetron administration did not improve its antiemetic efficacy after intracranial tumour resection surgery in children. ( Bhatia, A; Bithal, PK; Dash, HH; Dash, M; Pandia, MP; Subramaniam, B; Subramaniam, K, 2007) |
| "Oral ondansetron (8 mg) was given 1 h prior to temozolomide administration." | 2.71 | Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. ( Abdulkarim, B; Armand, JP; Cioloca, C; Djafari, L; Djazouli, K; Faivre, S; Guillamo, JS; Osorio, M; Parker, F; Raymond, E; Vera, K, 2004) |
| " Further detailed pharmacokinetic studies of irinotecan in patients receiving concomitant therapy with enzyme-inducing anticonvulsants are required so that rational dosing recommendations can be provided for this patient population." | 1.31 | Influence of phenytoin on the disposition of irinotecan: a case report. ( Berg, S; Bernstein, M; Blaney, SM; Cherrick, I; Kuttesch, N; Murry, DJ; Salama, V, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, MP | 1 |
| Woodring, S | 1 |
| Randazzo, DM | 1 |
| Friedman, HS | 1 |
| Desjardins, A | 1 |
| Healy, P | 1 |
| Herndon, JE | 1 |
| McSherry, F | 1 |
| Lipp, ES | 1 |
| Miller, E | 1 |
| Peters, KB | 1 |
| Affronti, ML | 1 |
| Sardi, I | 1 |
| Fantappiè, O | 1 |
| la Marca, G | 1 |
| Giovannini, MG | 1 |
| Iorio, AL | 1 |
| da Ros, M | 1 |
| Malvagia, S | 1 |
| Cardellicchio, S | 1 |
| Giunti, L | 1 |
| de Martino, M | 1 |
| Mazzanti, R | 1 |
| Frost, F | 1 |
| Dailler, F | 1 |
| Duflo, F | 1 |
| Demir, HA | 1 |
| Batu, ED | 1 |
| Yalçın, B | 1 |
| Civelek, E | 1 |
| Saçkesen, C | 1 |
| Büyükpamukçu, M | 1 |
| Behnam-Motlagh, P | 1 |
| Sandström, PE | 1 |
| Henriksson, R | 1 |
| Grankvist, K | 1 |
| Vera, K | 1 |
| Djafari, L | 1 |
| Faivre, S | 1 |
| Guillamo, JS | 1 |
| Djazouli, K | 1 |
| Osorio, M | 1 |
| Parker, F | 1 |
| Cioloca, C | 1 |
| Abdulkarim, B | 1 |
| Armand, JP | 1 |
| Raymond, E | 1 |
| Nathan, PC | 1 |
| Tomlinson, G | 1 |
| Dupuis, LL | 1 |
| Greenberg, ML | 1 |
| Ota, S | 1 |
| Bartels, U | 1 |
| Feldman, BM | 1 |
| Subramaniam, K | 1 |
| Pandia, MP | 1 |
| Dash, M | 1 |
| Dash, HH | 2 |
| Bithal, PK | 1 |
| Bhatia, A | 2 |
| Subramaniam, B | 2 |
| Kathirvel, S | 1 |
| Prakash, A | 1 |
| Shenoy, S | 1 |
| Murry, DJ | 1 |
| Cherrick, I | 1 |
| Salama, V | 1 |
| Berg, S | 1 |
| Bernstein, M | 1 |
| Kuttesch, N | 1 |
| Blaney, SM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
1 review available for ondansetron and Brain Neoplasms
| Article | Year |
|---|---|
[Ondansetron: a meta-analysis on its efficacy to prevent postoperative nausea and vomiting after craniotomy in adults and children].
Topics: Adult; Age Factors; Anesthetics, Intravenous; Antiemetics; Brain Neoplasms; Child; Craniotomy; Dose- | 2010 |
5 trials available for ondansetron and Brain Neoplasms
| Article | Year |
|---|---|
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Brain Neoplasms; Female; Glioma; Humans | 2020 |
Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazin | 2004 |
A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design.
Topics: Antiemetics; Antineoplastic Agents; Bayes Theorem; Brain Neoplasms; Child; Child, Preschool; Cisplat | 2006 |
Scheduled prophylactic ondansetron administration did not improve its antiemetic efficacy after intracranial tumour resection surgery in children.
Topics: Adolescent; Adult; Antiemetics; Brain Neoplasms; Child; Child, Preschool; Craniotomy; Double-Blind M | 2007 |
Effect of prophylactic ondansetron on postoperative nausea and vomiting after elective craniotomy.
Topics: Adolescent; Adult; Aged; Analgesia; Anesthesia; Antiemetics; Brain Neoplasms; Craniotomy; Dexamethas | 2001 |
4 other studies available for ondansetron and Brain Neoplasms
| Article | Year |
|---|---|
Delivery of doxorubicin across the blood-brain barrier by ondansetron pretreatment: a study in vitro and in vivo.
Topics: Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood | 2014 |
Anaphylactic reaction owing to ondansetron administration in a child with neuroblastoma and safe use of granisetron: a case report.
Topics: Anaphylaxis; Antiemetics; Antineoplastic Agents; Brain Neoplasms; Female; Granisetron; Humans; Infan | 2010 |
Ondansetron but not granisetron affect cell volume regulation and potassium ion transport of glioma cells treated with estramustine phosphate.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Size; Estramustine; Glioma; Granisetron; Hu | 2002 |
Influence of phenytoin on the disposition of irinotecan: a case report.
Topics: Adolescent; Anticonvulsants; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2002 |